How Much Does a Clinical Trial Actually Cost to Run?
Developing a new drug and bringing it to market costs an estimated 1 to 2.6 billion dollars. A large portion of that goes to clinical trials, and phase 3 trials alone can run to tens or hundreds of millions. Where does all that money go? The answer reveals a lot about how the research enterprise works, and why drug prices end up where they do.
Why trials are so expensive
The Clarity Clinical Solutions video on trial costs points to four reasons. Trials are long: a phase 3 study can take three to seven years from start to finish. They are complex: coordinating dozens or hundreds of sites across multiple countries takes massive logistical infrastructure. They are heavily regulated: every step must comply with good clinical practice, FDA regulations, and local law, which means extensive documentation and quality control. And failure is common: over 90% of drugs that enter phase 1 never reach the market, and the costs of those failures must be recovered from the few drugs that succeed.
Cost by phase
Costs vary dramatically by phase. Phase 1 trials typically cost 4 to 15 million dollars, with small numbers of healthy volunteers and a focus on safety. Phase 2 trials cost 20 to 50 million, testing dosing and efficacy in hundreds of patients. Phase 3 is the expensive one, ranging from 100 to 300 million dollars or more, with thousands of patients across dozens of sites worldwide. Phase 4 post-market studies cost 5 to 50 million. Put together, total clinical development for a single drug often lands between 800 million and over a billion dollars.
These figures come from the video. Independent research on drug development costs reaches the same general territory: the Tufts Center for the Study of Drug Development, which has tracked pharmaceutical R&D economics for decades, regularly publishes cost estimates in the billions of dollars for bringing a new medicine to market (Tufts CSDD). The FDA's own description of the drug development process shows why the bill gets so large: each phase builds on the last, and the later phases require the biggest, longest, and most expensive studies (FDA: drug development and approval process). The NIH's plain-language guide to clinical trials explains the phase structure the same way: what starts in small safety studies scales up to very large effectiveness trials (ClinicalTrials.gov: learn about clinical studies).
Where the money goes
The budget breaks down into a few big buckets. Clinical site costs, the payments to hospitals and clinics that conduct the trial, account for 30 to 40% of the budget, the largest single category. Patient recruitment and retention takes 10 to 15%, covering advertising, screening, and retention programs. Data management and biostatistics takes 15 to 20%: case report forms, database setup, monitoring, and statistical analysis. Regulatory affairs and ethics compliance takes 5 to 10%, covering IND filings, IRB reviews, and submissions. The rest goes to drug manufacturing, supply chain, project management, and overhead.
Site costs deserve a closer look, because they are what most people picture when they think of trial spending. Every patient visit generates costs for investigator time, coordinator time, nursing staff, lab processing, and facility use. A typical phase 3 visit costs between $2,000 and $5,000, and with hundreds of patients and dozens of visits each, site costs alone can reach tens of millions. Sites negotiate per-patient reimbursement with sponsors that covers both procedure costs and overhead. Complex trials with many procedures are the most expensive to run.
Sponsors and sites see costs from different sides. The sponsor pays for drug manufacturing, central lab services, data management, monitoring, and regulatory submissions, plus the per-patient site payments. The site pays staff salaries, facility overhead, equipment, and any non-reimbursed procedures. Many sites operate on thin margins, and if enrollment is slow or procedures are not reimbursed adequately, sites can lose money on a trial.
The hidden costs
Beyond the obvious line items sit the hidden ones. Protocol amendments, changing the protocol after a trial starts, can cost hundreds of thousands to millions of dollars each. Delays in regulatory or IRB approval add cost as fixed overhead keeps running. Slow enrollment extends the timeline and inflates every variable cost. Data queries that force sites to correct errors create extra work. And the cost of failed trials is enormous: drugs that look promising in phase 2 but fail in phase 3 often cost more than the trials that succeed.
Several factors push costs higher. Therapeutic area matters: oncology and cardiovascular trials are among the most expensive because of long follow-up, expensive imaging, and high patient numbers. Geographic complexity adds translation, local approvals, and varying ethical standards. Procedure intensity matters: frequent biopsies, complex imaging, and heavy lab work all add up. High dropout rates force sponsors to enroll more patients than planned. And evolving FDA and EMA standards require constant adaptation.
Cost per patient
Cost per patient varies widely. A simple phase 1 trial in healthy volunteers might cost $15,000 to $30,000 per patient. A complex phase 3 oncology trial can cost $50,000 to $100,000 or more per patient. The number depends on visit frequency, procedure complexity, length of follow-up, and region, with the US and Western Europe at the high end and emerging markets far cheaper. Understanding per-patient cost is how sponsors budget realistically and spot efficiency opportunities.
What brings costs down
The video lists proven levers. Decentralized trial designs cut site visits and facility overhead. Real-world data and electronic health records supplement traditional collection. Risk-based monitoring replaces 100% source data verification with targeted oversight. Smarter protocol design removes unnecessary procedures and visits. Centralized labs and imaging read centers improve efficiency. And patient recruitment analytics find eligible patients faster. Each strategy can trim 10 to 30% of costs.
The bottom line
Clinical trials are expensive because they are long, complex, and heavily regulated. The total cost of developing a single drug can exceed a billion dollars, most of it in trials. Site costs are the biggest line item, hidden costs like amendments and slow enrollment add millions more, and per-patient costs range from $15,000 to over $100,000. The numbers are staggering, but they reflect the complexity and rigor required to produce reliable evidence about whether a treatment works. Cutting costs without cutting corners is one of the biggest challenges, and opportunities, in clinical research today.
This article is based on the Clarity Clinical Solutions video "How Much Does a Clinical Trial Actually Cost to Run?" Watch it here: How Much Does a Clinical Trial Actually Cost to Run?
References
- Clarity Clinical Solutions video — the framework for this article: cost by phase, budget categories, hidden costs, per-patient costs, and cost-reduction strategies. https://www.youtube.com/watch?v=pvqm8n_spBc
- Tufts CSDD — Center for the Study of Drug Development, pharmaceutical R&D cost research. https://csdd.tufts.edu/
- FDA — Drug development and approval process overview. https://www.fda.gov/drugs/development-approval-process-drugs
- ClinicalTrials.gov — Learn about clinical studies and trial phases. https://clinicaltrials.gov/study-basics/learn-about-studies/learn-about-clinical-studies